Oral Drug Delivery Videos
-
Increasing Oral Delivery Precision For CNS Targets With Tris Pharma's Ketan Mehta
5/13/2026
Videocast host Tom von Gunden talks with CEO Ketan Mehta of Tris Pharma about innovations in oral delivery approaches to CNS disorders, such as ADHD, pain, and addiction. They discuss dosage form options, including liquid, solid, and powder, for leveraging polymer-based particle science to deliver stable, long-acting formulations. Among the advances discussed is precision targeting of payload release locations in the GI tract for optimal absorption.
-
Pharmaceutical Spray Drying: Sustainable Commercial Best Practices
Learn more about defining the spray drying process with an emphasis on specific enhancements to accommodate scale-up to commercial scale equipment of challenging applications or molecules.
-
Virtual Tour Of A CDMO Facility In Vandalia, OH
8/29/2024
Take a virtual tour of a CDMO facility in Vandalia, Ohio, that serves as a global R&D and commercial manufacturing center of excellence. The facility is just one of the seven state-of-the-art sites in the global network.
-
Improving Bioavailability, Drug Loads, And Pill Burdens Of Solid Dispersions
9/10/2024
Explore the pros and cons of marketed amorphous solid dispersions with so-far unpublished data as well as a green alternative to ASDs: best-in-class nanotechnology to manufacture nanocrystals.
-
Solvent-Free, Fusion-Based Amorphic Dispersion Process
7/11/2024
Discover a solvent-free, fusion-based process that leverages frictional and shear forces to rapidly convert crystalline drugs and polymers into amorphous solid dispersions (ASDs).
-
Integrated Strategies For Poor Solubility, Modified Release & Pediatrics
6/8/2022
Through case studies on modified release, poor solubility, and pediatrics, discover how integrating GMP manufacturing and clinical testing can rapidly accelerate development timelines for even the most challenging of molecules.
-
Post-Market Surveillance And Post-Approval Changes For Combination Products
1/12/2026
In this segment of the Drug Delivery Leader Live online event, Eying The Drug Delivery Regulatory Landscape: The 'Must See' Watch List For 2026, Chief Editor Tom von Gunden asks the panel to comment on post-market regulatory considerations and processes for combination products. Among the topics covered are post-approval changes, design outputs, patient safety, and various regulatory guidances.
-
Scaling Up A Revolutionary Amorphous Solid Dispersion Platform
3/19/2024
Process parameter and quality attribute relationships, including those for typical pre- and post-ASD unit operations, will be explored in the context of real-world examples.
-
Technology To Overcome Absorption Hurdles And Solubility Limitations
3/6/2024
For poorly soluble drugs, overcoming absorption hurdles can hinder development. Explore a solution that empowers researchers to overcome solubility limitations and accelerate drug development.
-
Partnership And Clinical Trial Strategies For Digitally Connected Devices
5/23/2025
In this segment of the Drug Delivery Leader Live online event, Innovations In Drug Delivery: Opportunities For Enhancing Familiar, Mature Approaches, James Wabby, head of global regulatory affairs for emerging device technologies and combination products at AbbVie, and Carolyn Dorgan, director of technical services at device design consultancy Suttons Creek, discuss key product development considerations when bringing digital connectivity solutions to drug delivery devices. These aspects include product and health authority partnerships, clinical studies, and regulatory approvals.